Current Report Filing (8-k)
December 11 2019 - 7:48AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of
The Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported)
December 11, 2019
INTEC
PHARMA LTD.
(Exact name of registrant as specified
in its charter)
Israel
|
|
001-37521
|
|
N/A
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
12 Hartom St.
Har Hotzvim
|
|
|
Jerusalem, Israel
|
|
9777512
|
(Address of principal executive offices)
|
|
(Zip Code)
|
+ 972-2-586-4657
(Registrant’s telephone number, including
area code)
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol
|
|
Name of each exchange
on which registered
|
Ordinary Shares, no, par value
|
|
NTEC
|
|
Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☒
On December 11, 2019,
Intec Pharma Ltd. issued a press release titled “Intec Pharma Provides Update on Novartis Feasibility and Option Agreement”.
A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: December 11, 2019
|
INTEC PHARMA LTD.
|
|
|
|
By:
|
/s/ Nir Sassi
|
|
|
Nir Sassi
|
|
|
Chief Financial Officer
|
2
Intec Parent (NASDAQ:NTEC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intec Parent (NASDAQ:NTEC)
Historical Stock Chart
From Apr 2023 to Apr 2024